美国糖尿病协会2025版糖尿病诊疗标准更新要点解读

董晓颖; 尹经霞; 李令; 余丽; 蒲丹岚; 廖涌

doi:10.13406/j.cnki.cyxb.003750

PDF(2172 KB)

重庆医科大学学报 ›› 2025, Vol. 50 ›› Issue (05) : 565-573. DOI: 10.13406/j.cnki.cyxb.003750

内分泌调控与代谢疾病

美国糖尿病协会2025版糖尿病诊疗标准更新要点解读

董晓颖 ¹ ,
尹经霞 ¹ ,
李令 ¹ ,
余丽 ¹ ,
蒲丹岚 ² ,
廖涌 ¹

作者信息 +

Interpretation of updated key points in the American Diabetes Association’s 2025 Standards of Care in Diabetes

Dong Xiaoying ¹ ,
Yin Jingxia ¹ ,
Li Ling ¹ ,
Yu Li ¹ ,
Pu Danlan ² ,
Liao Yong ¹

Author information +

History +

摘要

美国糖尿病协会（American Diabetes Association，ADA）多年来积极致力于糖尿病诊疗及日常照护标准的制定与推广，自1989年以来每年更新一版糖尿病诊疗标准，已成为糖尿病领域最权威的指南之一，得到了各国的认可和采纳。2024年12月10日，2025版糖尿病诊疗标准发布，融合了与糖尿病及其并发症和合并症相关的最新循证医学证据，旨在为临床医师、患者及家属、研究人员等提供其诊断、治疗、管理方面的指导意见。本文将择其重要更新要点进行解读。

Abstract

Over the years，the American Diabetes Association（ADA） has been actively committed to the development and promotion of standards for the diagnosis，treatment，and daily care of diabetes. Since 1989，it has updated the diabetes diagnosis and treatment standards every year，which have become one of the most authoritative guidelines in diabetes and have been recognized and adopted by various countries. On December 10，2024，the 2025 Standards of Care in Diabetes were released，incorporating the latest evidence-based medicine content related to diabetes and its complications and comorbidities. It aims to provide guidance on the diagnosis，treatment，and management of the condition for clinicians，patients and their families，and researchers. This article interprets the major updates from the Standards.

关键词

糖尿病 / 指南 / 美国糖尿病协会 / 诊断 / 治疗 / 管理

Key words

diabetes mellitus / guideline / American Diabetes Association / diagnosis / treatment / management

中图分类号

R587.1

引用本文

EndNote

Ris (Procite)

Bibtex

导出引用

董晓颖 , 尹经霞 , 李令 , 等. 美国糖尿病协会2025版糖尿病诊疗标准更新要点解读. 重庆医科大学学报. 2025, 50(05): 565-573 https://doi.org/10.13406/j.cnki.cyxb.003750

Dong Xiaoying, Yin Jingxia, Li Ling, et al. Interpretation of updated key points in the American Diabetes Association’s 2025 Standards of Care in Diabetes[J]. Journal of Chongqing Medical University. 2025, 50(05): 565-573 https://doi.org/10.13406/j.cnki.cyxb.003750

参考文献

列表( 原文顺序 | 文献年度倒序 | 文中引用次数倒序 ) 可视化分析

1	Sacks DB， Arnold M， Bakris GL，et al. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus[J]. Clin Chem，2023，69（8）：808-868. 本文引用 [1]

2	Eckhardt BJ， Holzman RS， Kwan CK，et al. Glycated hemoglobin a（1c） as screening for diabetes mellitus in HIV-infected individuals[J]. AIDS Patient Care STDS，2012，26（4）：197-201.

3	Kim PS， Woods C， Georgoff P，et al. A1C underestimates glycemia in HIV infection[J]. Diabetes Care，2009，32（9）：1591-1593. 本文引用 [1]

4	Holt RIG， DeVries JH， Hess-Fischl A，et al. The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association（ADA） and the European Association for the Study of Diabetes（EASD）[J]. Diabetologia，2021，64（12）：2609-2652. 本文引用 [1]

5	Khader YS， Dauod AS， El-Qaderi SS，et al. Periodontal status of diabetics compared with nondiabetics：a meta-analysis[J]. J Diabetes Complications，2006，20（1）：59-68. 本文引用 [1]

6	Casanova L， Hughes FJ， Preshaw PM. Diabetes and periodontal disease：a two-way relationship[J]. Br Dent J，2014，217（8）：433-437.

7	Eke PI， Thornton-Evans GO， Wei L，et al. Periodontitis in US adults：national health and nutrition examination survey 2009-2014[J]. J Am Dent Assoc，2018，149（7）：576-588. 本文引用 [1]

8	Kouidrat Y， Pizzol D， Cosco T，et al. High prevalence of erectile dysfunction in diabetes：a systematic review and meta-analysis of 145 studies[J]. Diabet Med，2017，34（9）：1185-1192. 本文引用 [1]

9	Broos B， Charleer S， Bolsens N，et al. Diabetes knowledge and metabolic control in type 1 diabetes starting with continuous glucose monitoring：future-PEAK[J]. J Clin Endocrinol Metab，2021，106（8）：e3037-e3048. 本文引用 [1]

10	Yoo JH， Kim G， Lee HJ，et al. Effect of structured individualized education on continuous glucose monitoring use in poorly controlled patients with type 1 diabetes：a randomized controlled trial[J]. Diabetes Res Clin Pract，2022，184：109209. 本文引用 [1]

11	Rubino F， Batterham RL， Koch M，et al. Lancet diabetes & endocrinology commission on the definition and diagnosis of clinical obesity[J]. Lancet Diabetes Endocrinol，2023，11（4）：226-228. 本文引用 [1]

12	Klein S， Gastaldelli A， Yki-Järvinen H，et al. Why does obesity cause diabetes?[J]. Cell Metab，2022，34（1）：11-20. 本文引用 [1]

13	Holt RIG， DeVries JH， Hess-Fischl A，et al. The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association（ADA） and the European Association for the Study of Diabetes（EASD）[J]. Diabetes Care，2021，44（11）：2589-2625. 本文引用 [1]

14	Mulinacci G， Todd Alonso G， Snell-Bergeon JK，et al. Glycemic outcomes with early initiation of continuous glucose monitoring system in recently diagnosed patients with type 1 diabetes[J]. Diabetes Technol Ther，2019，21（1）：6-10. 本文引用 [1]

15	Elbalshy M， Haszard J， Smith H，et al. Effect of divergent continuous glucose monitoring technologies on glycaemic control in type 1 diabetes mellitus：a systematic review and meta-analysis of randomised controlled trials[J]. Diabet Med，2022，39（8）：e14854.

16	Champakanath A， Akturk HK， Alonso GT，et al. Continuous glucose monitoring initiation within first year of type 1 diabetes diagnosis is associated with improved glycemic outcomes：7-year follow-up study[J]. Diabetes Care，2022，45（3）：750-753.

17	Weinstock RS， Xing DY， Maahs DM，et al. Severe hypoglycemia and diabetic ketoacidosis in adults with type 1 diabetes：results from the T1D Exchange clinic registry[J]. J Clin Endocrinol Metab，2013，98（8）：3411-3419.

18	Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group， Tamborlane WV， Beck RW，et al. Continuous glucose monitoring and intensive treatment of type 1 diabetes[J]. N Engl J Med，2008，359（14）：1464-1476.

19	Polonsky WH， Hessler D， Ruedy KJ，et al. The impact of continuous glucose monitoring on markers of quality of life in adults with type 1 diabetes：further findings from the DIAMOND randomized clinical trial[J]. Diabetes Care，2017，40（6）：736-741. 本文引用 [1]

20	Garg SK， Kaur G， Haider Z，et al. Efficacy of semaglutide in overweight and obese patients with type 1 diabetes[J]. Diabetes Technol Ther，2024，26（3）：184-189. 本文引用 [1]

21	Garg SK， Akturk HK， Kaur G，et al. Efficacy and safety of tirzepatide in overweight and obese adult patients with type 1 diabetes[J]. Diabetes Technol Ther，2024，26（6）：367-374. 本文引用 [1]

22	Type 1 diabetes impacts of semaglutide on cardiovascular outcomes（T 1-DISCO） [EB/OL].（2024-11-28）[2025-01-24]. https:// clinicaltrials.gov/study/NCT05819138?tab=results 本文引用 [1]

23	ADJUnct semaglutide treatment in type 1 diabetes（ADJUST-T 1D） [EB/OL].（2024-08-27）[2025-01-24]. https://clinicaltrials.gov/study/NCT05537233 本文引用 [1]

24	Mills KT， Chen J， Yang W，et al. Sodium excretion and the risk of cardiovascular disease in patients with chronic kidney disease[J]. Jama，2016，315（20）：2200. 本文引用 [1]

Whelton

， Carey

， Aronow

，et al.2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention，detection，evaluation，and management of high blood pressure in adults：executive summary：a report of the American college of cardiology/American heart association task force on clinical practice guidelines[J]. Hypertension，2018，71（6）：1269-1324.

本文引用 [1]

26	U.S. Department of Health and Human Services. Physical Activity Guidelines for Americans，2nd edition，2018[EB/OL].（2024-08-12）[2025-01-24]. https://health.gov/sites/default/files/2019-09/Physical_Activity_Guidelines_2nd_ edition.pdf 本文引用 [1]

基金

重庆市自然科学基金资助项目(CSTB2022NSCQ-MSX1271)

重庆市卫生健康委中医科研资助项目(2024WSJK192)

重庆市南岸区科卫联合医学科研资助项目(2023-03;2023-04)

PDF(2172 KB)

Accesses

Citation

Detail

段落导航

Received	Published
2025-01-25	2025-05-28
Issue Date
2025-06-16

选择文件类型/文献管理软件名称

选择包含的内容